Category 2 · Health & Life Sciences · AGI Future Foundation
Health & Life Sciences
Ten planned W3 series make up the Foundation’s health and life-sciences category, and they span the whole arc of health work: diagnosis, treatment, medicines, molecules, clinical method, health questions, and the records and data governance that hold the rest together. Every one of them is named in the April 2026 internal W3 series list, and every one of them is intended and planned — not formed, funded, or offered.
What this category is about
The category is called Health & Life Sciences because its ten series are about bodies, health, and the data that describes them — and because health is the domain where the Foundation’s honesty standard matters most. A wrong claim about a learning tool wastes a student’s afternoon; a wrong claim about a treatment can harm a person. That difference is why the articles in this category state their boundaries first and their ambitions second, and why several of them are deliberately thin: where almost nothing is verified beyond a name and a number, the honest article says so plainly instead of filling the space with invention.
It helps to read the ten series as a sequence rather than a list. Diagnostic.X (S03) is assessment: helping a human decide what is wrong, under an explicit safety mandate. Curable.X (S04) is treatment: the curative work that follows a diagnosis, still undefined in scope. BioPharma.Go (S05) is medicines: the biopharmaceutical work that treatment may involve, also undefined. Molecular. (S11) is the molecular scale beneath all of it: molecules, molecular data, and biotechnology, with no molecule files found to attribute to it. Gonstead.X (S13) is clinical method: the Gonstead approach to chiropractic care, a named tradition that would need licensed human leadership from the start. AskDoc.X (S14) is the front door: health questions, health information, and care navigation, explicitly not diagnosis or treatment. Then come the four record and governance series: Curable.Blockchain DAO (S17), a shared record for curative work; BioDAO.blockchain DAO (S18), biology and bioacoustics on a shared ledger; Genomic DAO (S27), consent and stewardship for genomic data; and Genome.Blockchain (S28), the verifiable record of that consent and custody.
Only one series in the category has a published direction beyond its name. Diagnostic.X is described on the Foundation site as AI diagnostics governed by an AGI-safety mandate, liability-isolated, and it is also the only series in the category with an anchored metaverse fabric: a Diagnostic.X world at 5.343, 101.566, with its fabric JSON live on GitHub Pages and its assets not yet hosted, so it does not render fully in Artemis. The other nine have no anchored fabric, and zero worlds are live on RP1 anywhere in the programme. The category therefore contains one series with a direction and a partial world, and nine series that are names awaiting definitions — and the articles report that unevenness without apology.
What the ten series share, beyond the category label, is a set of obligations that no other category imposes in quite the same way. Every health series must answer who is accountable when something goes wrong, and the answer is always a named human clinician or steward, never an agent. Every health series must answer what evidence its claims rest on, and the answer must be a trial, a result, and a review — not a pitch claim. Every health series that touches data must answer what it collects, under what consent, for how long, and who can see it. And every health series must say what it does not do, as clearly as what it does. Those obligations are the reason each article in this category lists its open questions instead of hiding them: the questions are the work, written down in advance.
Articles in this category
Each article below goes deep on one series: the work as planned, the DAO and stewardship model, the metaverse connection, what exists today against what is planned, how the series fits the mission, and the open questions it must answer. Read them in order, or start with the series whose question interests you most.
Article 04 — Diagnostic.X (S03)
AI diagnostics under a safety mandate, liability-isolated by design, with an anchored metaverse fabric at 5.343, 101.566. The only series in this category with a published direction beyond its name.
Article 05 — Curable.X (S04)
Curative, treatment-focused work, still undefined in scope — and a naming overlap with Curable.Blockchain DAO (S17) that no verified document explains.
Article 06 — BioPharma.Go (S05)
Biopharmaceutical work, still undefined — drug discovery, therapy development, manufacturing, delivery, or the tools that support them; no document chooses, and the “.Go” is unexplained.
Article 07 — Molecular. (S11)
Molecular science and biotechnology, still undefined. No molecule files were found to attribute to this series, and none are claimed.
Article 08 — Gonstead.X (S13)
The Gonstead approach to chiropractic care, planned. A named clinical tradition that would need licensed human leadership from the start — and no treatment or outcome claims.
Article 09 — AskDoc.X (S14)
Health questions, health information, and care navigation. Explicitly not diagnosis or treatment, with an urgent-help route as its first requirement.
Article 10 — Curable.Blockchain DAO (S17)
A shared, tamper-evident record for curative health work: diagnosis, treatment, and outcome recorded in order — with consent, correction, and privacy law still to be designed.
Article 11 — BioDAO.blockchain DAO (S18)
Biology and bioacoustics on a shared ledger, with the site copy “BioDao (WAVE bioacoustics)” as its only link to existing work — a label, not a specification. The anchored Biota world is not this series.
Article 12 — Genomic DAO (S27)
Consent, privacy, and shared benefit for genomic data — a stewardship body, not a data marketplace. A genome identifies a person and their relatives and cannot be changed if it leaks.
Article 13 — Genome.Blockchain (S28)
A verifiable record layer for genomic data: consent receipts, custody events, and access grants on-chain, with the genomic data itself kept off-chain. A ledger cannot make a steward honest.
How the category fits the Foundation mission
These ten series sit in the third tier of the Foundation’s intended three-tier architecture: below the Foundation itself, a filed California nonprofit public benefit corporation holding the mission standard — safe, equitable, and socially beneficial AI — and below W3 LLC, an intended Wyoming series LLC that would house the series as legally segregated sub-series. Only the apex tier is verified as filed; the middle tier and these series are intended, not formed. The Foundation acts as mission gate for the series below it, and its fundraising, as filed, is donation and grant only.
Three mechanisms from the Foundation’s governance pages would apply to these series if they are ever formed. The Fiduciary Shield is the proposed protection for a board that weighs safety and public benefit alongside returns — California benefit-corporation status expanding the business-judgment rule for benefit-considering decisions, under Corporations Code sections 14620–14621, with an annual benefit report under section 14630. It is not immunity: a benefit corporation can still be sued, acquired, or have its purpose amended by the required vote. Open Global Investment is the proposed model that decouples economics from control — Class A shares with one vote each for the global public, Class B with ten votes for screened partners and sovereigns, and Class C with one thousand votes, held only by the Foundation — but it belongs to the proposed for-profit benefit-corporation track, not to the filed nonprofit, and counsel must choose one track in writing before any solicitation. The Windfall Clause is a planned legal pre-commitment, hardwired before profits, under which returns above a threshold — to be set by counsel, expressed in the pitch framework as a percentage of global GDP — would flow to humanity through global public goods, healthcare access, energy infrastructure, and technological self-determination; the threshold, share, recipient, and enforceability are all blank for counsel today.
For this category, the mission fit is also a safety test. A diagnostic series that hides its uncertainty, a treatment series that promises what it cannot prove, or a genomic series that cannot describe one consent would fail the Foundation’s public-benefit standard before it started, whatever its legal form. The mission gate exists precisely for that test, and it is the reason each article in this category lists its open questions instead of hiding them: the questions are the gate, written down in advance.
← All articles | All 33 series | Foundation home
Questions about any series in this category go to [email protected]. This hub is not an offer of securities and not a solicitation of funds: no price, terms, or return is promised. Nothing on this page is legal, tax, or financial advice.